HSCT is associated with a high treatment-related mortality in the recipient (10% or higher)[citation needed], which limits its use to conditions that are themselves life-threatening. Major complications are veno-occlusive disease, mucositis, infections (sepsis), graft-versus-host disease and the development of new malignancies.
No comments:
Post a Comment